Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Tennessee: - Vanderbilt Breast Center at One Hundred Oaks — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- Saint Jude Children's Research Hospital — Memphis, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- Saint Jude Children's Research Hospital — Memphis, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Tennessee: - SCRI - TriStar Medical Group Children's Specialists — Nashville, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Tennessee: - Sarah Canon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Research…
Sponsor: Diakonos Oncology Corporation
NCT ID: NCT06805305
Sites in Tennessee: - Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…
Sponsor: Bayer
NCT ID: NCT06914128
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any …
Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06465199
Sites in Tennessee: - Monroe Carrell Jr. Children's Hospital at Vanderbilt — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor re…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05386108
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05535166
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
- Vanderbilt Ingram Cancer Center — Nashville, Tennessee
EARLY Phase 1 Recruiting Academic/Other
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
Sponsor: Eben Rosenthal
NCT ID: NCT07493447
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
EARLY Phase 1 Recruiting Academic/Other
This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
Sponsor: Vanderbilt-Ingram Cancer Center
NCT ID: NCT05996432
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
EARLY Phase 1 Recruiting Academic/Other
High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patien…
Sponsor: Eben Rosenthal
NCT ID: NCT07210632
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Tennessee: - Baptist (BHMCC) — Memphis, Tennessee
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
NA Recruiting Academic/Other
Low-grade gliomas (LGGs) are the most common brain tumors in children, and a subset of these tumors are treated definitively with focal radiation therapy (RT). These patients often survive for many years after receiving RT and experience l…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04065776
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
NA Recruiting Academic/Other
The objective of this study is to estimate the feasibility and acceptability of cognitive training in the virtual reality setting with children undergoing radiotherapy for brain tumors. To achieve this goal, the investigators plan to study…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05947045
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Recruiting Academic/Other
The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities) should be con…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT07085325
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee